Strategic partnering to enable cell therapy commercialization

As emerging cell therapies move towards the commercialization phase, focus has been placed on establishing scalable and reproducible manufacturing processes and incorporating innovations to streamline cell therapy manufacturing. This article will discuss how strategic partnering between biotech and pharma companies can facilitate the challenging transition of moving therapies through the commercialization pipeline.

Please enter your email to access content Read now